Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U.S. Food and Drug Administration approving VEPPANU (vepdegestrant) for the ...

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening the door to a new option for certain breast cancer patients. However, the ...

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer ...

The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand name Veppanu. Accordingly, the once-daily ...

Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.